Zorifertinib — Investigational Agent
EGFR Inhibitor · Phase 3 · Alpha Biopharma (Jiangsu)
Mechanism of Action
Oral EGFR tyrosine kinase inhibitor specifically engineered for high blood-brain barrier penetration, achieving free-drug CNS exposure to treat EGFR-mutant NSCLC with brain and leptomeningeal metastases.
Investigational Indications
- EGFR-mutant NSCLC with CNS metastases
- Leptomeningeal disease from EGFR-mutant NSCLC